Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more
Market Cap & Net Worth: Shanghai Hile Bio-tech (603718)
Shanghai Hile Bio-tech (SHG:603718) has a market capitalization of $431.80 Million (CN¥3.17 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #14173 globally and #3699 in its home market, demonstrating a 3.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Hile Bio-tech's stock price CN¥4.86 by its total outstanding shares 651904700 (651.90 Million).
Shanghai Hile Bio-tech Market Cap History: 2015 to 2026
Shanghai Hile Bio-tech's market capitalization history from 2015 to 2026. Data shows change from $1.95 Billion to $431.80 Million (-11.24% CAGR).
Shanghai Hile Bio-tech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Hile Bio-tech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.27x
Shanghai Hile Bio-tech's market cap is 2.27 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.59x
Shanghai Hile Bio-tech's market cap is 3.59 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.95 Billion | $316.58 Million | $95.40 Million | 6.16x | 20.43x |
| 2016 | $1.56 Billion | $343.34 Million | $85.54 Million | 4.55x | 18.25x |
| 2017 | $969.85 Million | $303.65 Million | $113.74 Million | 3.19x | 8.53x |
| 2018 | $1.12 Billion | $254.57 Million | $21.30 Million | 4.39x | 52.43x |
| 2019 | $1.13 Billion | $277.99 Million | -$26.41 Million | 4.06x | N/A |
| 2020 | $1.11 Billion | $259.13 Million | -$32.15 Million | 4.30x | N/A |
| 2021 | $1.35 Billion | $347.29 Million | $53.86 Million | 3.89x | 25.09x |
| 2022 | $867.25 Million | $299.99 Million | $121.61 Million | 2.89x | 7.13x |
| 2023 | $951.57 Million | $240.72 Million | $62.87 Million | 3.95x | 15.14x |
| 2024 | $613.94 Million | $271.04 Million | $171.18 Million | 2.27x | 3.59x |
Competitor Companies of 603718 by Market Capitalization
Companies near Shanghai Hile Bio-tech in the global market cap rankings as of March 18, 2026.
Key companies related to Shanghai Hile Bio-tech by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Shanghai Hile Bio-tech Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Hile Bio-tech's market cap moved from $1.95 Billion to $ 431.80 Million, with a yearly change of -11.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥431.80 Million | -20.33% |
| 2025 | CN¥541.98 Million | -11.72% |
| 2024 | CN¥613.94 Million | -35.48% |
| 2023 | CN¥951.57 Million | +9.72% |
| 2022 | CN¥867.25 Million | -35.82% |
| 2021 | CN¥1.35 Billion | +21.37% |
| 2020 | CN¥1.11 Billion | -1.47% |
| 2019 | CN¥1.13 Billion | +1.18% |
| 2018 | CN¥1.12 Billion | +15.14% |
| 2017 | CN¥969.85 Million | -37.87% |
| 2016 | CN¥1.56 Billion | -19.93% |
| 2015 | CN¥1.95 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shanghai Hile Bio-tech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $431.80 Million USD |
| MoneyControl | $431.80 Million USD |
| MarketWatch | $431.80 Million USD |
| marketcap.company | $431.80 Million USD |
| Reuters | $431.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.